Diversified Trust Co Buys Shares of 2,916 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Diversified Trust Co purchased a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,916 shares of the medical research company’s stock, valued at approximately $958,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. UMB Bank n.a. raised its holdings in shares of Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. Gladius Capital Management LP purchased a new position in shares of Bio-Rad Laboratories during the third quarter worth $32,000. Point72 Hong Kong Ltd purchased a new position in shares of Bio-Rad Laboratories during the third quarter worth $55,000. Headlands Technologies LLC purchased a new position in shares of Bio-Rad Laboratories during the second quarter worth $51,000. Finally, Quarry LP purchased a new position in shares of Bio-Rad Laboratories during the second quarter worth $59,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Royal Bank of Canada raised their target price on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an “outperform” rating in a report on Monday, December 9th. Finally, Citigroup raised their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $394.20.

Bio-Rad Laboratories Stock Up 0.2 %

BIO opened at $344.52 on Friday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $262.12 and a fifty-two week high of $387.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The company has a fifty day moving average of $339.69 and a two-hundred day moving average of $326.93. The stock has a market capitalization of $9.65 billion, a price-to-earnings ratio of -12.61 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same quarter last year, the business earned $2.33 earnings per share. The company’s revenue for the quarter was up 2.8% compared to the same quarter last year. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.